
Browsing restrictions can be lifted for a fee.
-19.31%
Cardio diagnostics holdings, inc.
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Cardio diagnostics holdings, inc. (CDIO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CDIO's short-term business performance and financial health. For the latest updates on CDIO's earnings releases, visit this page regularly.
According to the latest financial report, Cardio diagnostics holdings, inc. (CDIO) reported an Operating Profit of -1.71M with an Operating Margin of -59,950.86% this period, representing a decline of 21.48% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Cardio diagnostics holdings, inc. (CDIO) announced revenue of 2.86K, with a Year-Over-Year growth rate of -56.61%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Cardio diagnostics holdings, inc. (CDIO) had total debt of 486.6K, with a debt ratio of 0.06. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Cardio diagnostics holdings, inc. (CDIO) held Total Cash and Cash Equivalents of 6.37M, accounting for 0.72 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Cardio diagnostics holdings, inc. (CDIO) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -59,950.86%%, and net margin of -60,053.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CDIO's profit trajectory and future growth potential.
According to the past four quarterly reports, Cardio diagnostics holdings, inc. (CDIO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.98. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Cardio diagnostics holdings, inc. (CDIO)'s Free Cash Flow (FCF) for the period is -1.56M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 31.82% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.